Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Ligation
100%
Interleukin-12 (IL-12)
100%
OX40
100%
Cytotoxic T Cell Response
100%
Colon Metastasis
100%
4-1BB
100%
Combination Therapy
72%
Anti-OX40
72%
CD4+ T Cells
27%
Tumor
18%
Tumor Cells
18%
Large Tumors
18%
Survival Rate
18%
Adenovirus
18%
High Survival
18%
Tumor Burden
9%
Therapeutic Efficacy
9%
Treatment Modalities
9%
Cytotoxic T Lymphocytes
9%
Antitumor
9%
Patients with Advanced Cancer
9%
Immune Activation
9%
Gene Delivery
9%
Costimulation
9%
Immune Suppression
9%
Metastatic Colorectal Cancer (mCRC)
9%
Immune Tolerance
9%
Cytotoxic Activity
9%
Agonistic
9%
Agonistic Antibody
9%
Lymphocyte Activity
9%
In Vivo Depletion
9%
Tumor-infiltrating CD8+ T Cells
9%
Tumor-infiltrating Leukocytes
9%
Medicine and Dentistry
Immunotherapy
100%
Cytotoxic T-Cell
100%
Ligation
100%
Interleukin 12
100%
Metastatic Colon Cancer
100%
Combination Therapy
81%
Neoplasm
45%
T-Helper Cell
27%
Tumor Cell
18%
Survival Rate
18%
Adenoviridae
18%
Tumor
18%
Cytotoxicity
9%
Leukocyte
9%
Immunosuppressive Treatment
9%
Ex Vivo
9%
Colon Carcinoma
9%
Advanced Cancer
9%
Gene Targeting
9%
Immunological Tolerance
9%
Treatment Modality
9%
Immunology and Microbiology
Immunotherapy
100%
Colon
100%
Cytotoxic T Cell
100%
Interleukin 12
100%
T-Helper Cell
27%
Survival Rate
18%
Tumor Cell
18%
Adenoviridae
18%
Tumor-Associated Macrophage
9%
Cytotoxic T-Cell
9%
Cytotoxicity
9%
Tumor Volume
9%
Gene Targeting
9%
Pharmacology, Toxicology and Pharmaceutical Science
Immunotherapy
100%
Metastatic Colon Cancer
100%
Interleukin 12
100%
Combination Therapy
81%
Neoplasm
63%
Survival Rate
18%
Adenoviridae
18%
Cytotoxicity
9%
Advanced Cancer
9%
Gene Delivery
9%
Colon Carcinoma
9%
CD8 Antigen
9%